BiotechTube

mavrilimumab

Phase 2/3Completed
0 watching 0 views this week📈 Rising
60
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

COVID

Conditions

COVID

Trial Timeline

Jul 28, 2020 → Jan 14, 2022

NCT ID
NCT04447469

About mavrilimumab

mavrilimumab is a phase 2/3 stage product being developed by Kiniksa Pharmaceuticals for COVID. The current trial status is completed. This product is registered under clinical trial identifier NCT04447469. Target conditions include COVID.

Hype Score Breakdown

Clinical
22
Activity
15
Company
5
Novelty
7
Community
8

Clinical Trials (1)

NCT IDPhaseStatus
NCT04447469Phase 2/3Completed

Competing Products

20 competing products in COVID

See all competitors
ProductCompanyStageHype Score
Favipiravir + NitazoxanideStrides PharmaPhase 2
51
Human COVID-19 immunoglobulin (pH4) for intravenous injection + PlaceboSinopharmPhase 2
51
Mavrilimumab + PlaceboKiniksa PharmaceuticalsPhase 2
47
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Mavrilimumab + PlacebosKiniksa PharmaceuticalsPhase 2
47
Gimsilumab + PlaceboRoivant SciencesPhase 2
49
Icosapent ethylAmarin CorporationApproved
77
Icosapent ethylAmarin CorporationPhase 2
44
Bamlanivimab + Placebo + EtesevimabEli LillyPhase 3
77
GX-03 + Petrolatum ointmentTurn TherapeuticsPhase 2
44
Cytotoxic T LymphocytesTevogen BioPhase 1
25
InfliximabCelltrionPhase 2
52
CT-P63 and CT-P66 / PlaceboCelltrionPhase 3
77
DS-5670a + PlaceboDaiichi SankyoPhase 1/2
41
Enzalutamide PillAstellas PharmaPhase 2
52
S-892216 + PlaceboShionogiPhase 2
52
S-892216 + CarbamazepineShionogiPhase 1
33
EnsitrelvirShionogiPhase 2
52
FOY-305 + PlaceboOno PharmaceuticalPhase 3
77
DesidustatZydus LifesciencesPhase 2
52

Other Products from Kiniksa Pharmaceuticals

Rilonacept + PlaceboPhase 3
72
KPL-387 + PlaceboPhase 2/3
60
Mavrilimumab + PlacebosPhase 2
47
Mavrilimumab + PlacebosPhase 2
47
Vixarelimab + PlaceboPhase 2
47